The true test for new Alzheimer's drugs is in human clinical trials. Numerous treatments for Alzheimer's disease have been shown to be safe and to have some positive effect when tested in animal models of Alzheimer's disease. However, many of these potentially successful treatments have not been brought to human trials because of the increased cost and risk at this stage of research.

The goal of this Request for Proposals (RFP) is to increase the number of innovative treatments tested in humans for Alzheimer's disease, related dementias, and cognitive aging. This program will fund exploratory Phase 0 microdosing studies that assess preliminary target engagement and PK, Phase I safety testing, Phase 2 biomarker-based proof-of-concept clinical trials in patients, as well as IND-enabling studies to accelerate new drugs into trials. Through this PACT RFP, the ADDF is also interested in supporting biomarker-based trials to validate putative mechanisms of action for targeted pharmacological and non-pharmacological approaches to prevention.



Average Duration: Varies
Average Award: Up to $3 million


Must be received by 11:59 pm EST on the deadline date.

Letter of Intent: February 17, 2017
Invited Full Proposal: March 10, 2017

Letter of Intent: May 19, 2017
Invited Full Proposal: June 9, 2017

Letter of Intent: July 31, 2017
Invited Full Proposal: September 8, 2017

Letter of Intent: November 17, 2017
Invited Full Proposal: December 8, 2017

PACT Research Funding Priority Areas

  • Repurposing – Testing drugs approved for other indications in Alzheimer's disease clinical trials. Proposals should be hypothesis driven and drugs chosen for testing should target a rational mechanism(s) of action.
  • Novel therapies supported by preclinical in vivo data linking the therapeutic approach to Alzheimer’s disease or related dementias.

With regards to potential drug targets:

The ADDF is interested in novel targets that include, but are not limited to: neuroinflammation, protein degradation/autophagy, growth factor signaling, synaptic function/morphology, calcium regulation, energy utilization/mitochondria function, insulin sensitivity, epigenetics, ApoE function and cholesterol metabolism, vascular injury and the blood-brain barrier interface, cognitive enhancers, myelin changes, ischemia and oxidative stress, and tau-related toxicities.

The ADDF has limited interest in funding anti-amyloid approaches, including anti-amyloid aggregation programs, Abeta vaccine development, and beta- or gamma-secretase inhibition programs. The ADDF also has limited interest in funding cholinesterase inhibitor programs.

Funding Eligibility

  • Academic Investigators seeking to create and support innovative clinical programs in academic medical centers and universities.
  • Biotechnology companies with programs dedicated to Alzheimer's disease clinical development – New biotechnology company spinouts or existing biotechnology companies that demonstrate a clear need for non-profit funding are eligible to apply. Funding is provided through mission-related investments (MRIs) that require return on investment based upon scientific and/or business milestones.

Application Submission Guidelines

Review the Application Instructions before applying.

Multi-year proposals for up to $3 million will be considered.

All applicants are required to complete an electronic "Letter of Intent" (LOI) in the ADDF Funding Portal.




For program-related inquiries, please contact:
Andrew Koemeter-Cox, PhD, Scientific Program Officer
Phone: 212.901.7992

For application submission inquiries, please contact:
Grants and Contracts Team
Phone: 212.901.8019